Latest Biotechnology, Pharmaceutical and Healthcare News from Pharmafile

13:15 EST 18th December 2017 | BioPortfolio

Here are the most relevant search results for "Pharmafile" found in our extensive news archives from over 250 global news sources.

More Information about Pharmafile on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Pharmafile for you to read. Along with our medical data and news we also list Pharmafile Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pharmafile Companies for you to search.

Showing News Articles 1–25 of 901 from Pharmafile

Monday 18th December 2017

Novartis snaps up Priority Review Voucher for $130m

Novartis has got its wallet out to pick up a Priority Review Voucher (PRV) from Ultragenyx, forking out $130 million as part of the trade. The voucher will allow Novartis to speed up the review by the FDA of a pipeline drug of its choosing. In return, Ultragenyx receive a lump sum of $130 million for its development of Mepsevii – an enzyme replacement therapy for patients with mucopolysaccharido...

FDA approves Pfizer's Xeljanz for psoriatic arthritis

Pfizer has revealed that the FDA has passed marketing approval for Xeljanz (tofacitinib) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). read more

Apotex founder found dead at home

Apotex, the world’s seventh largest generics manufacturer, has lost its Chairman and founder, after Barry Sherman and his wife, Honey, were found dead at their house in Toronto, Canada. The exact cause of their deaths is still being investigated. The deaths are currently being treated as suspicious, with numerous reports suggesting that the bodies of the two individuals were found hanging from a...

Boehringer loses CFO over financial strategy dispute

Boehringer Ingelheim is set to part ways with its Chief Financial Officer Simone Menne after 16 months due to fundamental disagreements over strategy, it has emerged. The news comes sharply after another major pharma firm, Novartis, announced the departure of its President of Oncology. read more

Keytruda falls hard at gastric cancer hurdle

There was a time when PD-1/L1 immunotherapy treatments could do no wrong, blasting through indication after indication. However, the limits of the therapies are beginning to be found with a series of surprise failures across a number of indications. The first major one was Opdivo’s failure as first-line treatment in lung cancer, after this ice-breaker, of sorts, there have been a number of subse...

New PARP inhibitor hits UK market, offering distinct advantage

Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP inhibitor will be made available through private health insurance based on strong data revealed in recent clinical trials. The data showed that the drug was able to boost progression-free survival in both patients with the BRCA mutation (BRCA1 or BRCA2) and also in patients who did not di...

Friday 15th December 2017

Cancer Research UK agrees largest drug discovery collab to date

Cancer Research UK has announced that its subsidiary, Cancer Research Technology (CRT), and Celgene have agreed a drug discovery collaboration. The deal will see Cancer Research Technology take the lead on finding new candidates centred around mRNA translation. This is the process whereby cells construct proteins and could hold potential for targeting certain characteristics of cancer cells. read ...

Fierce local opposition to Teva’s restructure efforts

When Kare Shultz decided to take on the CEO position at Teva he would have known that he was setting himself up for a challenging time. In the opening period of his tenure, it seems he has taken the strategy to implement changes hard and fast – culminating in the decision to cut the global workforce of the company by over 25%. read more

Novartis' President of Oncology announces retirement

Novartis has announced that the President of its oncology business, Bruno Strigini, is to retire next year, citing personal reasons for the departure. He is due to step back from the company’s Executive Committee by 31 December and will hand over his role to his successor early next year, whom Novartis says it will announce in due time. read more

Thursday 14th December 2017

BMS partners again with the company behind Opdivo

Bristol-Myers Squibb has once again struck a deal with Ono Pharmaceutical for multiple programs, seeking to discover a boost to immunotherapy blockbuster Opdivo. Back in 2011, BMS made the decision to partner with Ono on nivolumab, a choice that would prove financially lucrative to both companies. The immunotherapy prospect became Opdivo – a treatment that scored $1.2 billion in revenue in the t...

Novartis, Abbott targeted by Indian watchdog over allegations of price collusion

Novartis, Abbott, Emcure Pharma and USV have become the targets of an investigation by the Competition Commission of India (CCI) over allegations they worked together to hike the price of blockbuster anti-diabetic drug vildagliptin, sold under the brand name Galdus. read more

FDA launches new method for antibiotic prescription

The fight against the growth of antibiotic resistance has become a major talking point internationally in recent years and the FDA has announced its own method to aid the effort. read more

'Mind-blowing' gene therapy could herald a cure for haemophilia, study shows

A team of clinical researchers at Barts Health NHS Trust and Queen Mary University of London have reported that a single gene therapy treatment has proved remarkably effective in the treatment of haemophilia A one year after infusion, with patients displaying normal levels of the missing protein that characterises the condition. read more

What will Pfizer do with its second Remicade biosimilar?

Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these is in partnership with Celltrion. The FDA approved its second biosimilar, Ixifi, but with it already heavily invested in the commercialisation of Inflectra, alongside Celltrion, the question remains about what Pfizer will choose to do with its second version? read more

Daiichi Sankyo: Two steps forward, one step back in cancer deals

Daiichi Sankyo had a busy day in terms of its deals in oncology, not only did it tear up its agreement with Nektar Therapeutics but it also signed up for two more deals yesterday. The two newly inked deals are with Vernalis and Puma Biotech, both deals are within oncology. Daiichi’s work with Vernalis will involve drug discovery, as the two companies will work with Vernalis’ fragment and struc...

Wednesday 13th December 2017

Sanofi sees pipeline fruition in 2018

In news that Sanofi will no doubt be hoping should divert attention away from the Dengvaxia scandal, the company revealed that it expects to take a number of projects to Phase 3 and to file for regulatory approval in 2018. 2017 has been a year to forget for the company; it has failed to secure the major acquisitions that have been called for to bolster its pipeline and its blockbuster product for ...

Blood cancer patients over 75 are significantly underrepresented in clinical trials, study finds

The FDA’s first comprehensive analysis of clinical trial enrolment in older patients with blood cancers has revealed that the population of patients over 75 are significantly underrepresented, particularly when considering the high incidence of these conditions in this age group. Currently, one in five patients diagnosed with blood cancer is over 75, and this figure is expected to grow as the po...

FDA cracks down on snortable chocolate powder

The FDA has taken action on Coco Loko and Legal Lean Syrup, both made by Arco Globus Trading LLC, after the former was brought to US nationwide attention by Senate Minority Leader, Charles Schumer, back in July. The senator referred to the product as “cocaine on training wheels” and the FDA has taken action by sending a warning letter to the company for selling unapproved new drug and misbrand...

J&J's Darzalex cuts risk of disease progression and death by 50%, new study shows

Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and prednisone, was able to reduce the risk of disease progression or death by 50% in newly diagnosed multiple myeloma patients for whom autologous stem cell transplantation is not appropriate. The findings led senior study author Jesus F San-Miguel to remark ...

Tumultuous times at Teva continue, with Chairman exit

In the latest addition to a number of high profile exits from Teva, previous interim Chief Executive and the company’s chairman, Yitzhak Peterburg, has resigned from the company with immediate effect. Peterburg joins Michael Hayden, CSO, Rob Koremans, CEO of specialty drugs, and Dipankar Bhattacharjee, CEO of its generics business, in leaving the business since Kare Shultz joined as its CEO. rea...

Tuesday 12th December 2017

FDA approves first short-acting, follow-on biologic of Lilly's Humalog insulin product

The FDA has announced its approval of Sanofi’s Admelog (insulin lispro), the first follow-on biologic version of Eli Lilly’s Humalog – a short-acting insulin authorised for the improvement of glycaemic control in in adults and children aged three years and older with type 1 diabetes and adults with type 2 diabetes. The data which prompted the decision was derived from two Phase 3 trials comp...

Latest US company accused of price gouging, after 2,469% increase

It seems that no matter how much bad press comes their way, certain pharmaceutical companies are more than happy to take a little heat to make quick money. The latest to come to light is Avondale Pharmaceutical and the huge prices increases on two drugs it bought before subsequently hiking the price. read more

Single, high-dose vaccine could provide better protection against cholera outbreaks, new research shows

A team of researchers at the University of Maryland School of Medicine (UMSOM) has been assessing the effectiveness of a single high-dose live vaccine in the treatment of cholera, as opposed to the traditional two-dose inactivated vaccine approach, with the hope of more successfully protecting vulnerable populations in large, recent outbreaks of the disease. read more

Sanofi issues US-wide recall for arthritis product, after adverse events

Sanofi has announced a recall of 12,380 syringes of its Synvisc-One product for the treatment of osteoarthritis, after it was noted that a particular batch was associated with unusually high levels of adverse events. The issue, reported by The Boston Globe, originates from Sanofi’s facility in Ridgefield, New Jersey, and relates to a batch of 18,000 syringes under the identification number 7RSL0...

Ionis scores huge breakthrough in Huntington’s, Roche licenses drug

Ionis Pharmaceuticals has revealed findings from its Phase 1/2a study into a treatment for Huntington’s disease and the strong data has been met with enthusiasm from all quarters. The findings from an early stage trial were strong enough for Roche to immediately jump in to license the treatment, parting with $45 million in the process. The aim of study was objectively to determine safety of the ...

Quick Search

News Quicklinks